Temozolomide + RT For GBM
from OncoPharm Hosted by John Bossaer
The Landmarks of OncoPharm series return to discuss the now standard-of-care temozolomide + RT for glioblastoma multiforme (GBM) Stupp et al: https://www.nejm.org/doi/full/10.1056/NEJMoa043330 Effect of MGMT (the gene, not the band) on temozolomide effect (from the same NEJM issue) referenced, thought not discussed in this episode: https://www.nejm.org/doi/full/10.1056/NEJMoa043331
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 16 minutes long.
When was this OncoPharm episode published?
This episode was published on September 1, 2022.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.